Dermapharm Maintains Stability Amid Portfolio Adjustments

Dermapharm Holding SE reported stable earnings despite making portfolio adjustments, confirming its guidance for 2025 and showing robust growth in branded pharmaceuticals. The company, based in Grünwald, Germany, saw a slight revenue decrease of 2.3%, reaching EUR 869.4 million in the first nine months of 2025, down from EUR 890.1 million the previous year. This was primarily due to restructuring efforts in the parallel import business focused on contribution margins.

The "Branded pharmaceuticals" segment experienced strong organic growth of 5.8%. Meanwhile, adjusted EBITDA for non-recurring items fell by 1.8% to EUR 236.0 million. The restructuring measures laid the groundwork for sustainable growth, with CEO Dr. Hans-Georg Feldmeier expressing confidence in meeting the company's full-year guidance.

While the company navigates challenges in its parallel import business, the robust performance of its branded pharmaceuticals segment highlights a successful strategic focus on high-margin products.